<DOC>
	<DOC>NCT00558168</DOC>
	<brief_summary>Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer</brief_summary>
	<brief_title>Electronic Study for Anastrozole Pharmacovigilance Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions. Metastatic breast cancer patients, previous hormonal therapy, other malignancies.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Anastrazole</keyword>
	<keyword>safety</keyword>
	<keyword>early breast cancer</keyword>
</DOC>